Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab

Jeanette Halskou Hesselvig, Alexander Egeberg, Nikolai Dyrberg Loft, Claus Zachariae, Kristian Kofoed, Lone Skov

25 Citations (Scopus)

Abstract

Monitoring of biological treatment efficacy for psoriasis is based on clinical evaluation and patient's quality of life. However, long-term correlation between Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) in real life has not been studied in patients treated with ustekinumab. All patients with psoriasis treated with ustekinumab at our department were included (n = 120) in this study. Correlation analyses between the change in PASI and DLQI and the individual subquestions in DLQI were performed using Spearman's rank correlation coefficient. A correlation value of 0.57 (p-value < 0.001) and 0.45 (p-value < 0.001) between PASI and DLQI were found in the period baseline - 4 months and baseline - 12 months, respectively. In DLQI subquestions, the greatest association was found for the questions on "Symptoms and feelings". Objective improvements in the severity of psoriasis were weakly to moderately associated with improvements in quality of life in patients with psoriasis treated with ustekinumab.

Original languageEnglish
JournalActa Dermato-Venereologica
Volume98
Issue number3
Pages (from-to)335-339
ISSN0001-5555
DOIs
Publication statusPublished - 2018

Keywords

  • Journal Article

Fingerprint

Dive into the research topics of 'Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab'. Together they form a unique fingerprint.

Cite this